Dr. Calais explains the utility of PSMA PET prior to RT for unfavorable intermediate-risk or high-risk prostate cancer. Dr. Saby George continues with the survival implications and ramifications from the CheckMate 214 long-term data. Dr. Saby George provides details on CheckMate 67T for the utility of subcutaneous nivolumab for advanced or metastatic ccRCC. Dr. Powles offers his thoughts on the latest OS data from EV-302 for patient subgroups and immune-related toxicity. Dr. Powles gives his unique feedback on what to make of KEYNOTE-564 and how aRCC frontline options should be compared. The outcomes related to sacituzumab govitecan for patients with variant histologies are highlighted. The potential for sequencing erdafitinib and EV for patients with FGFR2/3-altered disease is considered. The impact of squamous and other histologies on outcomes with EV are dissected. The design of UNITE, patients sampled, and outcomes with EV after switch maintenance avelumab are explored. Dr. Tawagi provides her thoughts on treatment selection and sequencing for mUC, especially after progression on EV/pembro. Drs. Daneshmand and Wallis highlight two trials in progress in NMIBC: ABLE-41 and PIVOT-006. Dr. Geynisman highlights the CheckMate 274 study into long-term survival following treatment with adjuvant nivolumab. Dr. Grivas describes the advancements in the discussion around avelumab maintenance at this year's meeting. Dr. Brian Rini discusses KEYNOTE-564 long-term survival data and LITESPARK-005 PROs. Dr. Plimack comments on long-term survival data from nivolumab/ipilimumab in the CheckMate 214 study as well as other data. Tanya Jindal discusses the safety and efficacy of neoadjuvant atezolizumab prior to radical cystectomy for MIBC. Dr. Grünwald describes the CheckMate 914 Part B analysis and investigating adjuvant nivo for patients with localized RCC. Dr. Grünwald details the CLEAR study and a subgroup analysis on the efficacy of lenvatinib/pembrolizumab for aRCC. Dr. Gupta details some of her latest research and describes the importance of multiple new initiatives in bladder cancer. Dr. Wallis highlights his population-based research on treatment intensification shortcomings in de novo mCSPC.